Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scrip's Stock Tracker - July 2009

This article was originally published in Scrip

Executive Summary

Optimism was out of fashion in the US for most of last month. On July 22, First Trust Advisors chief economist Brian Wesbury dared to talk on the Yahoo techticker of what he called a looming V-shaped recovery, and of US GDP growth of 3.5% in H2 2009.

You may also be interested in...



APACMed: Johnson & Johnson On Using ‘Big’ For Good In The COVID-19 Challenge

Johnson & Johnson's Ashley McEvoy explains how the global medtech business should change, seen through the lens of the coronavirus pandemic.

Philips Previews Five-Year Plan As Connected Care Returns Group To Growth In Q3

COVID-19 business volatility continues to impact the medtech industry, but Royal Philips is targeting modest comparable sales growth for 2020 after posting quarterly growth of 10%.

COVID-19 Antigen Tests Offer New Diagnostic Option In Germany

Germany’s COVID-19 testing strategy now permits the use and reimbursement of coronavirus antigen tests.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1122620

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel